Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Champions Oncology (CSBR) Shares Repurchased (2023)

Champions Oncology has reported Shares Repurchased over the past 3 years, most recently at $32000.0 for Q4 2023.

For Q4 2023, Shares Repurchased changed N/A year-over-year to $32000.0; the TTM value through Jul 2024 reached $32000.0, down 95.27%, while the annual FY2024 figure was $634000.0, 756.76% up from the prior year.
Shares Repurchased for Q4 2023 was $32000.0 at Champions Oncology, down from $602000.0 in the prior quarter.
Over five years, Shares Repurchased peaked at $602000.0 in Q3 2023 and troughed at $32000.0 in Q4 2023.